THP3 Antibody

What is THRAP3 and what cellular functions does it perform?

THRAP3 (thyroid hormone receptor associated protein 3) functions primarily as a transcriptional coactivator in cellular processes. It is a protein with a calculated molecular weight of 109 kDa, though it is commonly observed at 109-130 kDa in experimental conditions . THRAP3 plays essential roles in transcriptional regulation pathways and has been implicated in various cellular functions related to gene expression control. Research methodologies for studying its functions typically involve knockout/knockdown experiments followed by transcriptome analysis to identify affected gene networks.

What sample types show consistent THRAP3 expression?

Based on validated antibody studies, THRAP3 has been consistently detected in multiple cell lines and tissue types. Positive Western blot detection has been confirmed in HeLa cells, LNCaP cells, 3T3-L1 cells, U-251 cells, and human brain tissue . For immunohistochemistry applications, THRAP3 has been successfully detected in human ovary tumor tissue and thyroid cancer tissue . When designing experiments targeting THRAP3, researchers should consider these validated sample types as positive controls.

What are the recommended applications for THRAP3 antibodies?

THRAP3 antibodies have been validated for multiple experimental applications:

For optimal results, researchers should titrate antibodies in their specific experimental systems .

What are the critical parameters for successful Western blot detection of THRAP3?

For Western blot applications, THRAP3 antibodies require specific optimization steps. When using polyclonal antibodies like 19744-1-AP, the recommended dilution range is 1:500-1:2000 . Since THRAP3 has a calculated molecular weight of 109 kDa but can appear between 109-130 kDa, researchers should use appropriate molecular weight markers.

Sample preparation is critical - complete cell lysis with protease inhibitors is essential for consistent results. For antigen retrieval in tissue samples, TE buffer pH 9.0 is recommended, though citrate buffer pH 6.0 can be used as an alternative . Researchers should optimize protein loading (typically 20-40 μg of total protein per lane) and exposure times to avoid signal saturation while maintaining sensitivity.

How should researchers design validation experiments for THRAP3 antibodies?

Proper validation of THRAP3 antibodies requires multiple approaches:

• Positive and negative control samples: Use known THRAP3-expressing cells (HeLa, LNCaP) as positive controls . THRAP3 knockdown or knockout samples serve as negative controls.

• Cross-validation with multiple antibodies: Compare results from different THRAP3 antibody clones (such as 19744-1-AP and 85093-3-RR) .

• Specificity testing: Perform peptide competition assays using the immunizing peptide.

• Application-specific validation: For each application (WB, IHC, IF), specific validation protocols should be employed, including signal localization analysis (THRAP3 should show primarily nuclear localization).

• Molecular weight confirmation: Verify that the detected band appears at the expected molecular weight range (109-130 kDa) .

What are the optimal conditions for immunohistochemical detection of THRAP3?

For successful IHC applications with THRAP3 antibodies:

• Tissue preparation: Use formalin-fixed, paraffin-embedded sections with proper fixation time (12-24 hours).

• Antigen retrieval: Primary recommendation is TE buffer pH 9.0, with citrate buffer pH 6.0 as an alternative .

• Antibody dilution: Start with 1:50 dilution and optimize between 1:20-1:200 range .

• Incubation conditions: Overnight incubation at 4°C typically yields better results than shorter incubations at room temperature.

• Detection system: HRP-based detection systems with DAB substrate provide consistent results for THRAP3 visualization.

• Controls: Include human ovary tumor or thyroid cancer tissue as positive controls .

How is THRAP3 being investigated in cancer research?

THRAP3 has emerged as an important focus in cancer research, particularly in studies of ovarian and thyroid cancers. Recent research has demonstrated that THRAP3 plays a role in transcriptional regulation pathways that may influence cancer progression. Methodologically, researchers are investigating THRAP3 using several approaches:

• Expression correlation studies: Analysis of THRAP3 expression levels in cancer vs. normal tissues, with IHC validation in human ovary tumor and thyroid cancer tissues .

• Functional studies: Gene silencing approaches (siRNA, CRISPR) to examine the effects of THRAP3 depletion on cancer cell proliferation, migration, and response to therapy.

• Mechanistic investigations: Co-immunoprecipitation experiments to identify THRAP3 interaction partners in cancer cells, revealing potential regulatory networks.

• Therapeutic potential: Emerging studies are exploring whether THRAP3 represents a potential therapeutic target, similar to other nuclear proteins involved in transcriptional regulation.

What are the emerging applications of advanced antibody technologies in cancer research?

Recent developments in antibody technology are transforming cancer research and therapeutic approaches:

• Tertiary lymphoid structures (TLS) antibodies: New research shows that antibodies produced in TLS could target tumor cells and cells in the surrounding environment, potentially enhancing immunotherapies for cancer patients. Researchers led by Dr. Jose Conejo-Garcia have found that TLS produce highly clonal immunoglobulin A (IgA) and immunoglobulin G (IgG) antibodies that may maintain immune pressure against malignant progression .

• Trispecific antibodies: Novel trispecific antibodies like AZD5492 are being developed for cancer treatment. Unlike conventional bispecific antibodies that engage all T cells through CD3, these trispecific antibodies preferentially target CD8+ T cells, potentially reducing cytokine release syndrome and neurotoxicity while maintaining cancer-killing efficacy2.

• AI-assisted antibody discovery: Vanderbilt University Medical Center has received $30 million to develop AI technology for therapeutic antibody discovery. This project aims to build a massive antibody-antigen atlas and develop AI algorithms to engineer antigen-specific antibodies, addressing inefficiencies in traditional antibody discovery methods .

What methodological approaches are emerging for antibody engineering in research?

Advanced methodological approaches for antibody engineering include:

• Cloning antibodies from tertiary lymphoid structures: Researchers are extracting DNA specifically from TLS to examine antibody function and clone these antibodies to restrain tumor growth. This approach has shown promise in ovarian cancer models .

• Multi-specific antibody design: Development of trispecific antibodies like AZD5492 that can engage multiple targets simultaneously (CD20 on B cells and CD8+ T cells) for more precise therapeutic effects and reduced toxicity2.

• AI-driven antibody design: Computational approaches using machine learning to predict antibody-antigen interactions and design optimized antibodies. This approach aims to overcome bottlenecks in traditional discovery methods, making the process more efficient and accessible .

• Humanized mouse models: Preclinical testing of novel antibodies in humanized mice engrafted with B cell tumors to evaluate efficacy and toxicity profiles before advancing to clinical trials2.

What are common technical challenges when using THRAP3 antibodies and how can they be resolved?

Researchers frequently encounter several technical issues when working with THRAP3 antibodies:

• Variable molecular weight detection: THRAP3 can appear between 109-130 kDa on Western blots . This variation may be due to post-translational modifications or alternative splicing. Resolution: Use positive control samples with known THRAP3 expression and verify with multiple antibody clones.

• Background in immunostaining: High background can obscure specific THRAP3 signals. Resolution: Optimize blocking conditions (5% BSA or 5% normal serum from the secondary antibody host species), increase washing steps, and titrate primary antibody concentration.

• Inconsistent immunoprecipitation results: THRAP3 interactions may be sensitive to lysis conditions. Resolution: Compare different lysis buffers (RIPA vs. NP-40), adjust salt concentration, and ensure proper protein-protein crosslinking if required.

• Epitope masking in fixed tissues: Formaldehyde fixation can mask THRAP3 epitopes. Resolution: Optimize antigen retrieval conditions, testing both TE buffer pH 9.0 and citrate buffer pH 6.0 .

How should researchers interpret and validate unexpected THRAP3 antibody results?

When faced with unexpected results:

• Multiple band patterns: If multiple bands appear in Western blots, perform validation with:

  • siRNA/shRNA knockdown to identify specific bands

  • Peptide competition assays

  • Comparison with alternative antibody clones

  • Mass spectrometry analysis of immunoprecipitated proteins

• Discrepant localization: If THRAP3 shows unexpected cellular localization:

  • Verify fixation conditions

  • Compare multiple antibodies targeting different epitopes

  • Use fractionation experiments to confirm localization biochemically

  • Consider cell type-specific or condition-dependent localization patterns

• Quantitative differences across techniques: If THRAP3 levels differ between techniques:

  • Evaluate sample preparation differences

  • Consider epitope accessibility in different applications

  • Assess technical variability through replicate experiments

  • Use absolute quantification methods (with recombinant standards) for direct comparison

What considerations are important when selecting between different THRAP3 antibody products?

Several factors should influence antibody selection:

• Epitope location: Consider whether the antibody recognizes N-terminal, C-terminal, or internal epitopes. For example, antibody 19744-1-AP recognizes the C-terminus of THRAP3 .

• Validation breadth: Review the extent of validation across applications. Some antibodies are validated for multiple applications (WB, IHC, IF, IP, CoIP) , while others may have more limited validation.

• Publication record: Evaluate the antibody's publication history in relevant applications and research areas.

• Host species compatibility: Consider experimental constraints related to host species and isotype, particularly for multiplexing experiments.

• Lot-to-lot consistency: Review manufacturer quality control data for consistency across production lots.

• Application-specific performance: An antibody optimal for Western blot may not be ideal for IHC or IP applications. Select based on your primary application needs.

How might AI technologies transform THRAP3 antibody development and applications?

AI technologies are poised to revolutionize antibody research through several approaches:

• AI-driven antibody design: Machine learning algorithms can predict antibody-antigen interactions and optimize binding affinity and specificity for THRAP3, potentially yielding antibodies with superior performance characteristics .

• High-throughput screening augmentation: AI can analyze large datasets from antibody screening campaigns to identify patterns and select optimal candidates against THRAP3, accelerating discovery timelines.

• Epitope mapping prediction: Computational methods can predict optimal epitopes on THRAP3 for antibody targeting, focusing development efforts on the most promising regions.

• Cross-reactivity prediction: AI algorithms can assess potential cross-reactivity with related proteins, improving antibody specificity before experimental validation .

• Application-specific optimization: Customized AI models could predict which antibody characteristics will perform best in specific applications (WB, IHC, IP), allowing for application-tailored development.

What emerging therapeutic applications might involve THRAP3 antibodies?

While current THRAP3 antibodies are primarily research tools, several therapeutic directions show potential:

• Cancer immunotherapy: Given THRAP3's presence in ovarian and thyroid cancer tissues , antibody-based approaches targeting THRAP3 or its pathways could emerge as potential therapeutic strategies.

• Antibody-drug conjugates (ADCs): THRAP3 antibodies could potentially deliver cytotoxic payloads specifically to cancer cells expressing this protein.

• Diagnostic applications: THRAP3 antibodies might serve as diagnostic tools for certain cancer types, particularly if expression patterns correlate with disease progression or treatment response.

• Combinatorial approaches: Integration with emerging trispecific antibody technologies2 could create more effective and targeted therapeutic approaches for THRAP3-expressing cancers.

• Modulation of transcriptional regulation: Since THRAP3 functions in transcriptional coactivation, therapeutic approaches might target this pathway to modify gene expression in disease states.